pegvaliase

Details

Files
Generic Name:
pegvaliase
Project Status:
Complete
Therapeutic Area:
Phenylketonuria
Manufacturer:
BioMarin Pharmaceutical Inc.
Brand Name:
Palynziq
Project Line:
Reimbursement Review
Project Number:
SR0712-000
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of patients with phenylketonuria (PKU) aged 16 years and older who have inadequate blood phenylalanine control (blood phenylalanine levels greater than 600 µmol/L) on existing management.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
​For the treatment of patients with phenylketonuria (PKU) aged 16 years and older who have inadequate blood phenylalanine control (blood phenylalanine levels greater than 600 µmol/L) on existing management.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.

Procedural review: CADTH accepted a procedural review request from BioMarin Pharmaceutical Inc. (Canada) for the final recommendation from the CADTH Canadian Drug Expert Committee (CDEC) for SR0712-000 Palynziq.

Status: Concluded.

Description: This matter was concluded following adjudication by a procedural review panel (“the panel”). In its decision, the panel found that CADTH and CDEC acted in accordance with the Procedures for CADTH Reimbursement Reviews for the review of Palynziq.

The panel’s decision was provided in a memorandum report to CADTH . CADTH has prepared a response to the findings of the procedural review.

Outcome: The CDEC final recommendation of “Reimburse With Conditions” is upheld for Palynziq.

Key Milestones2
Call for patient/clinician input openNovember 02, 2021
Call for patient/clinician input closedJanuary 05, 2022
Clarification:

- Patient input submission received from the Canadian PKU and Allied Disorders (CanPKU)

Submission receivedDecember 23, 2021
Submission acceptedJanuary 14, 2022
Review initiatedJanuary 17, 2022
Draft CADTH review report(s) provided to sponsor for commentMarch 31, 2022
Deadline for sponsors commentsApril 11, 2022
CADTH review report(s) and responses to comments provided to sponsorMay 12, 2022
Expert committee meeting (initial)May 25, 2022
Draft recommendation issued to sponsorJune 07, 2022
Draft recommendation posted for stakeholder feedbackJune 16, 2022
End of feedback periodJune 30, 2022
Clarification:

- Reconsideration: major revisions requested by sponsor

Expert committee meetingOctober 26, 2022
Final recommendation issued to sponsor and drug plansNovember 09, 2022
Final recommendation postedNovember 25, 2022
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)November 23, 2022
CADTH review report(s) postedFebruary 14, 2023
Procedural review concluded March 13, 2023
Clarification:

- Final recommendation upheld